Systemic Lupus Erythematosus – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Systemic Lupus Erythematosus – Pipeline Review, H1 2017’, provides an overview of the Systemic Lupus Erythematosus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus

The report reviews pipeline therapeutics for Systemic Lupus Erythematosus by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic Lupus Erythematosus therapeutics and enlists all their major and minor projects

The report assesses Systemic Lupus Erythematosus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Ablynx NV

ACEA Biosciences Inc

Actelion Ltd

AiCuris GmbH & Co KG

Amgen Inc

Argos Therapeutics Inc

Asahi Kasei Pharma Corp

Atlantic Bio Sci LLC

Aurinia Pharmaceuticals Inc

Azano Pharmaceuticals Inc

Bio-Path Holdings Inc

Biogen Inc

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

Celldex Therapeutics Inc

Cellular Biomedicine Group Inc

Corestem Inc

CuraVac Inc

Daiichi Sankyo Company Ltd

Deltanoid Pharmaceuticals Inc

Domainex Ltd

Eisai Co Ltd

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Genentech Inc

Genosco Inc

Genovax Srl

GlaxoSmithKline Plc

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Immungenetics AG

Immunomedics Inc

Immunwork Inc

Immupharma Plc

Invion Ltd

Janus Biotherapeutics Inc

Johnson & Johnson

K-Stemcell Co Ltd

Kadmon Corp LLC

Karyopharm Therapeutics Inc

KPI Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

LSK BioPartners Inc

MacroGenics Inc

MedAnnex Ltd

Medestea Research & Production SpA

MedImmune LLC

Merck KGaA

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Mount Tam Biotechnologies Inc

Nektar Therapeutics

Neovacs SA

Nippon Chemiphar Co Ltd

Novartis AG

Nuevolution AB

Omeros Corp

Pfizer Inc

Principia Biopharma Inc

Ra Pharmaceuticals Inc

RedHill Biopharma Ltd

Redx Pharma Plc

Rigel Pharmaceuticals Inc

Sarepta Therapeutics Inc

SBI Biotech Co Ltd

Seattle Genetics Inc

Shire Plc

Stemline Therapeutics Inc

Takeda Pharmaceutical Company Ltd

TheraMAB LLC

TxCell SA

UCB SA

Xencor Inc

XTL Biopharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Systemic Lupus Erythematosus - Overview 7

Systemic Lupus Erythematosus - Therapeutics Development 8

Systemic Lupus Erythematosus - Therapeutics Assessment 24

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 38

Systemic Lupus Erythematosus - Drug Profiles 78

Systemic Lupus Erythematosus - Dormant Projects 379

Systemic Lupus Erythematosus - Discontinued Products 384

Systemic Lupus Erythematosus - Product Development Milestones 386

Appendix 395

List of Tables

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Systemic Lupus Erythematosus – Pipeline by AbbVie Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Ablynx NV, H1 2017

Systemic Lupus Erythematosus – Pipeline by ACEA Biosciences Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Actelion Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by AiCuris GmbH & Co KG, H1 2017

Systemic Lupus Erythematosus – Pipeline by Amgen Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Argos Therapeutics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Asahi Kasei Pharma Corp, H1 2017

Systemic Lupus Erythematosus – Pipeline by Atlantic Bio Sci LLC, H1 2017

Systemic Lupus Erythematosus – Pipeline by Aurinia Pharmaceuticals Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Azano Pharmaceuticals Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Bio-Path Holdings Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Biogen Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Biotest AG, H1 2017

Systemic Lupus Erythematosus – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Systemic Lupus Erythematosus – Pipeline by Bristol-Myers Squibb Company, H1 2017

Systemic Lupus Erythematosus – Pipeline by Celgene Corp, H1 2017

Systemic Lupus Erythematosus – Pipeline by Celldex Therapeutics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Corestem Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by CuraVac Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Deltanoid Pharmaceuticals Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Domainex Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Eisai Co Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Eli Lilly and Company, H1 2017

Systemic Lupus Erythematosus – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Genentech Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Genosco Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Genovax Srl, H1 2017

Systemic Lupus Erythematosus – Pipeline by GlaxoSmithKline Plc, H1 2017

Systemic Lupus Erythematosus – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Immungenetics AG, H1 2017

Systemic Lupus Erythematosus – Pipeline by Immunomedics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Immunwork Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Immupharma Plc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Invion Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Janus Biotherapeutics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Johnson & Johnson, H1 2017

Systemic Lupus Erythematosus – Pipeline by K-Stemcell Co Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Kadmon Corp LLC, H1 2017

Systemic Lupus Erythematosus – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by KPI Therapeutics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Lead Discovery Center GmbH, H1 2017

Systemic Lupus Erythematosus – Pipeline by LSK BioPartners Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by MacroGenics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by MedAnnex Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Medestea Research & Production SpA, H1 2017

Systemic Lupus Erythematosus – Pipeline by MedImmune LLC, H1 2017

Systemic Lupus Erythematosus – Pipeline by Merck KGaA, H1 2017

Systemic Lupus Erythematosus – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Systemic Lupus Erythematosus – Pipeline by Mount Tam Biotechnologies Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Nektar Therapeutics, H1 2017

Systemic Lupus Erythematosus – Pipeline by Neovacs SA, H1 2017

Systemic Lupus Erythematosus – Pipeline by Nippon Chemiphar Co Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Novartis AG, H1 2017

Systemic Lupus Erythematosus – Pipeline by Nuevolution AB, H1 2017

Systemic Lupus Erythematosus – Pipeline by Omeros Corp, H1 2017

Systemic Lupus Erythematosus – Pipeline by Pfizer Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Principia Biopharma Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Ra Pharmaceuticals Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by RedHill Biopharma Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Redx Pharma Plc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Rigel Pharmaceuticals Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Sarepta Therapeutics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by SBI Biotech Co Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by Seattle Genetics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Shire Plc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Stemline Therapeutics Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Systemic Lupus Erythematosus – Pipeline by TheraMAB LLC, H1 2017

Systemic Lupus Erythematosus – Pipeline by TxCell SA, H1 2017

Systemic Lupus Erythematosus – Pipeline by UCB SA, H1 2017

Systemic Lupus Erythematosus – Pipeline by Xencor Inc, H1 2017

Systemic Lupus Erythematosus – Pipeline by XTL Biopharmaceuticals Ltd, H1 2017

Systemic Lupus Erythematosus – Dormant Projects, H1 2017

Systemic Lupus Erythematosus – Dormant Projects, H1 2017 (Contd..1), H1 2017

Systemic Lupus Erythematosus – Dormant Projects, H1 2017 (Contd..2), H1 2017

Systemic Lupus Erythematosus – Dormant Projects, H1 2017 (Contd..3), H1 2017

Systemic Lupus Erythematosus – Dormant Projects, H1 2017 (Contd..4), H1 2017

Systemic Lupus Erythematosus – Discontinued Products, H1 2017

Systemic Lupus Erythematosus – Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports